Abstract
Background
Platelet Rich Plasma-Platelet concentrate (PRP-PC), Buffy Coat poor-platelet concentrate (BCPC), and Apheresis — PC were prepared and their therapeutic efficacy were assessed in thrombocytopenic patients.
Study design and methods
PRP-PC and BC-PC were prepared from whole blood and Apheresis-PC by automated cell separator. The post transfusion efficacy of transfused platelets was assessed at 1 hour and 20 hours by corrected count increment (CCI) and percentage recovery (PR).
Results
A total of 60 patients’ (20 each for PRP-PC, BC-PC and Apheresis-PC) were enrolled in this study. Forty one patients received therapeutic and nineteen received prophylactic transfusion support. Patients with aplastic anemia 43% (25/60) and acute leukemia 38% (23/60) formed a majority of study population. Platelet dosage of patients’ received PRP-PC, BC-PC and apheresis-PC were 2.4±0.82 × 1011 (mean±SD), 2.2±0.83 × 1011 (mean±SD) and 4.14±1.82 × 1011 (mean±SD) and ranged from 1.16–4.11 × 1011, 1.04−4.20 × 1011 and 1.22−8.90 × 1011 respectively. There was significantly increase in inter-transfusion interval with Apheresis-PC than with PRP-PC and BC-PC recipients [(Mean±S.D.), 4.7±1.33 days Vs 2.7±0.82 days Vs 2.5±0.7 days respectively] (p < 0.05).
Conclusions
Patients transfused with apheresis-PC had received higher platelet dosage than PRP-PC and BC-PC and this difference was statistically significant (p < 0.001). The post transfusion platelet counts and increments at 1 hour and 20 hours were significantly higher with apheresis-PC than PRP-PC and BC-PC (p < 0.001). However, the corrected count increment (CCI) and percentage recovery (PR) in all three groups were comparable. There was significantly increase in inter-transfusion interval with apheresis-PC than PRPPC and BC-PC (p < 0.05).
Keywords: Random donor platelets, Buffy coat poor-platelet concentrate, Platelet Rich Plasma-Platelet concentrate, Thrombocytopenic patients
Full Text
The Full Text of this article is available as a PDF (90.0 KB).
Glossary
- RDP
Random donor platelets
- SDP
single donor platelets
- PRP-PC
Platelet Rich Plasma-Platelet concentrate
- BC-PC
Buffy coat poor-platelet concentrate
- PC
platelet concentrate
- CCI
corrected count increment
- PR
percentage recovery.
References
- 1.Hersh J.K., Hom E.G., Brecher M.E. Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion-dependent patient. Transfusion. 1998;38:637–644. doi: 10.1046/j.1537-2995.1998.38798346631.x. [DOI] [PubMed] [Google Scholar]
- 2.Perrota PL, Anderson KC (2003) Blood banking and trans-fusion medicine — Basic Principles and Practice. Churchill Livingstone, Philadelphia: 181–205
- 3.Sniecinski I., O’Donnell M.R., Norwicki B., Hill L.R. Prevention of refractoriness of HLA-alloimmunization using filtered blood products. Blood. 1988;71:1402–1407. [PubMed] [Google Scholar]
- 4.Brecher ME, Butch SH, Cathouri AR (2000) Technical Manual: American Association of Blood Bank (AABB), 13th edition. Bethesda, Maryland 346
- 5.Mosteller R.D. Simplified calculation of body surface area. N Engl J Med. 1987;317:1098. doi: 10.1056/NEJM198710223171717. [DOI] [PubMed] [Google Scholar]
- 6.Friedberg R.C., Donelly S.F., Boyd J.C., Gray L.S., Minz P.D. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood. 1993;81:3128–3134. [PubMed] [Google Scholar]
- 7.Herman J.H. Transfusion therapy: Clinical principles and practice. Bethesda Maryland: AABB Press; 1999. pp. 65–79. [Google Scholar]
- 8.Baer M.R., Bloomfield C.D., Kasprisin D.O. Controversies in transfusion medicine; prophylactic platelet transfusion therapy. Pro Transfusion. 1992;32:377–380. doi: 10.1046/j.1537-2995.1992.32492263454.x. [DOI] [PubMed] [Google Scholar]
- 9.Consensus conference Platelet transfusion therapy. JAMA. 1987;257:1777–1780. doi: 10.1001/jama.257.13.1777. [DOI] [PubMed] [Google Scholar]
- 10.Haker L.A., Roskos L., Cheung E. Effective and efficient platelet transfusion strategies that maintain hemostatic protection. Transfusion. 1998;38:619–621. doi: 10.1046/j.1537-2995.1998.38798346628.x. [DOI] [PubMed] [Google Scholar]
- 11.O’Connell B., Lee E.J., Schiffer C.A. The value of 10 minutes post transfusion platelet counts. Transfusion. 1998;28:66–67. doi: 10.1046/j.1537-2995.1988.28188127957.x. [DOI] [PubMed] [Google Scholar]
- 12.Davis K.V., Slichter S.J., Coras L. corrected Count Increment and Percentage Platelet Recovery as measures of post transfusion platelet response: Problem and Solution. Transfusion. 1999;39:586–592. doi: 10.1046/j.1537-2995.1999.39060586.x. [DOI] [PubMed] [Google Scholar]
- 13.Norol F., Bierling P., Roudot-Thoroval F., et al. Platelet transfusion: a dose-response study. Blood. 1998;92:1448–1453. [PubMed] [Google Scholar]
- 14.Klumpp R.T., Herman J.H., Gaughan J.P., et al. Clinical consequences of alterations in platelet transfusion dose: A prospective randomized double blind trial. Transfusion. 1999;39:674–681. doi: 10.1046/j.1537-2995.1999.39070674.x. [DOI] [PubMed] [Google Scholar]
- 15.Tinmouth A.T., Freedman J. Prophylactic Platelet Transfusions: Which Dose is the Best? A Review of Literature. Tran Med Rev. 2003;17:181–193. doi: 10.1016/S0887-7963(03)00018-X. [DOI] [PubMed] [Google Scholar]